Table 2: Main characteristics and results of the eligible studies for evaluation of event-free survival.

Study
(author/year)
CountryNumber of patientsAge (y)ALP cut-off (IU/L)Enneking stageHR (95% CI)Follow-up (m)
Median (range)

Mialou et al., 2005 [29]France4813.5 (2–19)500IIIB2.7 (1.5–4.8)NA
Lee et al., 2007 [42]Korea45<15AII4.55 (1.22–16.99)54 (6–153)
Yalçın et al., 2008 [30]Turkey5513 (7–17)NAII-III1.11 (0.54–2.31)NA
Kim et al., 2009 [32]Korea6715.7 (3.8–64.4)NAII1.84 (0.84–4.07)59.9
Chou et al., 2009 [31]USA91NANAIII2.83 (1.68–4.79)89 (1–141)
Ferrari et al., 2012 [36]Italy20914 (4–39)AII1.71 (1.09–2.67)76 (31–115)
Berner et al., 2015 [41]Norway237NAAΔII-III1.78 (1.26–2.52)NA

NA: not available, A: available (see the footnotes for details), HR: hazard ratio, CI: confidence interval, y: year(s), and m: month(s).
: ALP cut-off: 2–10 y 420 IU/L; 10-11 y 560 IU/L; 12–15 y male 495 IU/L; 12-13 y female 420 IU/L; 14-15 y female 230 IU/L.
: ALP cut-off: 2–10 y 350 IU/L; 10–13 y female 400 IU/L; 13–15 y male 500 IU/L; 20–50 y 100 IU/L; other childhood age 300 IU/L.
Δ: ALP cut-off: 0–17 y 400 IU/L; >17 y 105 IU/L.